Insmed Incorporated (NASDAQ:INSM) Insider Sells $114,423.84 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,744 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $65.61, for a total value of $114,423.84. Following the sale, the insider now owns 90,013 shares of the company’s stock, valued at $5,905,752.93. This represents a 1.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total value of $570,146.48.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $68.12 on Friday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm’s 50-day moving average price is $71.57 and its two-hundred day moving average price is $73.12. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock has a market capitalization of $12.41 billion, a P/E ratio of -12.19 and a beta of 0.84.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the firm posted ($1.06) EPS. As a group, sell-side analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analysts Set New Price Targets

INSM has been the subject of a number of research reports. Stifel Nicolaus decreased their price target on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Morgan Stanley lifted their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Jefferies Financial Group initiated coverage on Insmed in a research note on Tuesday, May 13th. They issued a “buy” rating and a $105.00 price target for the company. Finally, Wells Fargo & Company lifted their price target on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

Hedge Funds Weigh In On Insmed

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Insmed by 0.3% during the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after buying an additional 49,149 shares during the period. Darwin Global Management Ltd. boosted its position in shares of Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after buying an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Insmed by 1.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after buying an additional 219,131 shares during the period. Capital International Investors boosted its position in shares of Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after buying an additional 593,206 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after buying an additional 273,759 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.